Todos Medical

TONIGHT: REGISTER to listen in on Wednesday Sept 27, 2023 to learn more about how is being used successfully as a dietary supplement by leading functional medicine physicians helping patients with

us02web.zoom.us/webinar/regist…

One platform to connect | Zoom Modernize workflows with Zoom's trusted collaboration tools: including video meetings, team chat, VoIP phone, webinars, whiteboard, contact center, and events.

Todos Medical (OTCQB: TOMDF) initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics. The currently circulating strain of H5N1, which has been the most transmissible and most deadly to date, has successfully crossed over from birds to mammals, with various land and sea animals, including skunks, foxes, raccoons, bears, minks, mountain lions, sea lions, seals and dolphins having confirmed H5N1 infection at death.

Read the full press release here http://bit.ly/3xpc04l

Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics February 14, 2023 9:06am EST Download as PDF New York, NY, and Tel Aviv, ISRAEL, Feb. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB...

Todos Medical's (OTCQB: TOMDF) 3CL Pharma Awarded Oral and Poster Presentations at World Congress 2022.

Read the full press here http://bit.ly/3GRzvJj

(drug candidate) (dietary supplement, not approved to diagnose, treat, prevent or cure any disease)

Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022 Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022 November 29, 2022 8:23am EST Download as PDF New York, NY, and Tel Aviv, ISRAEL, Nov. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagn...

Todos Medical to attend World Antiviral Congress 2022 from the 28th of November, 2022 – 1st of December, 2022 in Loews Coronado Bay Resort, San Diego.

Read the full press here http://bit.ly/3XrhCqD

Todos Medical to Attend World Antiviral Congress Todos Medical to Attend World Antiviral Congress November 22, 2022 8:31am EST Download as PDF New York, NY, and Tel Aviv, ISRAEL, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announc...

Todos Medical (OTCQB: TOMDF) Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network. Affy Services, Smart Automated Retail Network Parent Company, to also represent Todos for traditional shelf space to Its 20,000+ US-based retail grocery store locations.

Read the full press release here http://bit.ly/3hFx3e9

Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network November 16, 2022 7:30am EST Download as PDF Affy Services, Smart Automated Retail Network Parent Company, to Also Represent Todos for Traditional Shelf Space to Its 20,000+ US-based R...

Todos Medical (OTCQB: TOMDF) Announces Third Quarter 2022 Financial Results. The company saw an 89% increase in Q3/2022 quarterly revenues as compared with Q3/2021.

Read the full press release here http://bit.ly/3UzWRHg

Todos Medical Announces Third Quarter 2022 Financial Results Todos Medical Announces Third Quarter 2022 Financial Results November 15, 2022 8:30am EST Download as PDF Related Documents Audio Earnings Webcast 10-Q Filing PDF HTML XBRL ZIP XLS HTML § 89% increase in Q3/2022 quarterly revenues as compared with Q3/2021 § Earnings and business update call to be ...

Todos Medical (OTCQB: TOMDF) will host the third quarter of 2022 earnings and business update conference call on November 15th, 2022 at 8:30am ET.

Conference call details here https://bit.ly/3O8rtwY

Todos Medical to Host Third Quarter 2022 Earnings and Business Update Conference Call on November 15, 2022 Todos Medical to Host Third Quarter 2022 Earnings and Business Update Conference Call on November 15, 2022 November 14, 2022 6:26pm EST Download as PDF NEW YORK, NY, AND TEL AVIV, ISRAEL, Nov. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medic...

Todos Medical terminates Tollovid™ Products License & Distribution Agreement with T-Cell Protect Hellas S.A. T-Cell Protect has acknowledged the termination and has agreed to remove Todos Medical’s name and logo from its marketing materials, and will remove any reference to Dr. Dorit Arad’s work being associated with T-Cell Protect Hellas S.A. products.

Read the full press release here http://bit.ly/3hAkAZ6

Todos Medical Terminates Tollovid™ Products License & Distribution Agreement with T-Cell Protect Hellas S.A. Todos Medical Terminates Tollovid™ Products License & Distribution Agreement with T-Cell Protect Hellas S.A. November 10, 2022 10:33am EST Download as PDF New York, NY, and Tel Aviv, ISRAEL, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive m...

Todos Medical (OTCQB: TOMDF) President and CEO Gerald Commissiong will be making a corporate presentation and providing a corporate update to the investment community at BioFuture™ NYC 2022 on Tuesday November 8th, 2022 at 3:30 pm.

https://bit.ly/3zKCv5Q

Todos Medical Announces BioFuture™ NYC 2022 Presentation Todos Medical Announces BioFuture™ NYC 2022 Presentation November 04, 2022 7:50am EDT Download as PDF New York, NY, and Tel Aviv, ISRAEL, Nov. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, tod...

Todos Medical (OTCQB: TOMDF) President and CEO Gerald Commissiong interviewed with Impact Wealth Magazine where they discussed the important work he is doing as a Key Opinion Leader in this space and how their natural supplement has helped sufferers of find relief and a path to recovery. This revolutionary data is just the beginning of this life-changing alternative medicine.

Read the full article here https://bit.ly/3yCQLgk

Impacting Lives for the Better with CEO Gerald Commissiong - Impact Wealth CEO Gerald Commissiong is not just your average CEO. Todos Medical’s leader of operations is an entrepreneur, key opinion leader, but most notably he is a man on a mission. His brand is about using common sense solutions to solve large complex challenges. Most of the health challenges in today’s...

Todos Medical (OTCQB: TOMDF) CLIA/CAP Lab Provista Diagnostics submits Emergency Use Authorization application for MonkeyPox PCR Test to US FDA. The EUA application was submitted for lesion-based PCR. The sensitivity achieved for the currently available lesion-based laboratory-developed test (LDT) is 0.95 viral copies per reaction (0.095 copies/ul).

Read the full press release here https://bit.ly/3VuD8tg

Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for MonkeyPox PCR Test to US FDA Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for MonkeyPox PCR Test to US FDA October 14, 2022 9:09am EDT Download as PDF New York, NY, and Tel Aviv, ISRAEL, Oct. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire --Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensiv...

President and CEO of Todos Medical (OTCQB: TOMDF), Gerald Commissiong discussed the development of Videssa®. The first blood test of its kind to accurately detect the presence or absence of breast cancer in women with abnormal or difficult-to-interpret imaging findings.

Watch the full interview here https://bit.ly/3yFcrbH

Todos Medical Ltd CEO interviewed with BronxNet to discuss breast cancer test blood test Videssa® October 5, 2022 - President and CEO of Todos Medical Ltd, Gerald Commissiong discussed the development of Videssa®. The first blood test of its kind to accur...

Todos Medical (OTCQB: TOMDF) provides corporate update for the year ahead and 2023 to shareholders. The company will give a presentation at the Emerging Growth Conference on Wednesday, October 12, 2022 at 2:00pm EST

Register here https://bit.ly/3RSK2pr

Read the full press release here https://bit.ly/3Tb6qLB

Todos Medical Provides Corporate Update Todos Medical Provides Corporate Update October 11, 2022 10:56am EDT Download as PDF 3CL Pharma prepares to crowdfund for Long COVID trials of Tollovir™ and Tollovid™ CEO to Present at Emerging Growth Conference on Wednesday, October 12, 2022 at 2pm ET New York, NY, and Tel Aviv, ISRAEL, Oct. 11...

Todos Medical (OTCQB: TOMDF) Announces Successful Pilot Launch of Suite of PCR Testing Services by CLIA/CAP Lab Provista Diagnostics. The PCR testing services include Urinary Tract Infection (UTI), Wound, Respiratory Pathogen (RP), Gastrointestinal (GI), Sexually Transmitted Infections (STI), COVID and MonkeyPox panels. The Company’s offering delivered 24h turnaround time for results, a local patient service center to facilitate sample collection, and pharmacist interpretation to assist the physician with prescription decision-making. The Company successfully onboarded over 10 physician practices in the area, primarily specialists and skilled nursing facilities, and is now preparing to fully launch in Dunnellon and neighboring rural jurisdictions in preparation to launch in strategic underserved communities nationwide.

Read the full press release here https://bit.ly/3CBEqLD

Todos Medical Announces Successful Pilot Launch of Suite of PCR Testing Services by CLIA/CAP Lab Provista Diagnostics Todos Medical Announces Successful Pilot Launch of Suite of PCR Testing Services by CLIA/CAP Lab Provista Diagnostics October 06, 2022 8:00am EDT Download as PDF Rural FL launch serves as proof of concept for underserved regions nationally NEW YORK, NY and TEL AVIV, Israel, Oct. 06, 2022 (GLOBE NEWS...

We're excited to join the B2i Digital family and to attend the ROTH Capital Partners Healthcare Opportunities Conference on October 6th, 2022. We hope to see you there!
https://lnkd.in/gy5GH3Tn

We want to welcome Todos Medical (OTCQB: TOMDF) as both a new member of the B2i Digital family of Featured Companies and to the ROTH Capital Partners Healthcare Opportunities Conference (October 6th, 2022) section of B2i Digital at https://hubs.li/Q01nKjyt0

Todos Medical Ltd. is an in vitro diagnostics company focused on the development of novel blood tests for the early detection of cancer and neurodegenerative disorders by developing novel blood tests that are reliable, affordable and minimally invasive.

We look forward to seeing the continued results from Gerald Commissiong, Jorge Leon, Paula T. Trzepacz, M.D., Daniel Hirsch, Chris Gross, Elise Brownell, PhD, Andrew Blumenthal, Ilanit Halperin, Dr Joseph Wee and the rest of the Todos Medical team!

Todos Medical (OTCQB: TOMDF) Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform. The key allowed claim for Infrared (IR) Spectroscopy System patent application was surrounding the system of collecting blood, obtaining FTIR spectrum from peripheral blood lymphocytes, and an output unit, configured to generate an output indicative of the presence of a solid tumor. The claim allowed for the patent application Analysis of Benign Tumors was related to the necessary conditions to capture consistent data to yield actionable results.

Read the full press release here https://bit.ly/3rhNFu8

Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform September 30, 2022 9:59am EDT Download as PDF New York, NY, and Tel Aviv, ISRAEL, Sept. 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehens...

Todos Medical Announces USPTO Trademark Notice of Allowance for 3CL Protease Biomarker Diagnostics TolloTest™. The test is designed to quantify 3CL protease, which is being measured for correlation with infectiousness and potentially a key feature of the SARS-CoV-2 viral persistence pathology in Long COVID. TolloTest is a potential companion biomarker test for the Company’s 3CL protease inhibitor dietary supplement Tollovid and a companion diagnostic for its Phase 2 asset Tollovir for hospitalized COVID. TolloTest can be commercialized as a rapid point-of-care test in single use and mass screening formats, as an at-home test for single use, and as a laboratory developed test (LDT) for use in high complexity CLIA labs and mobile labs for patient monitoring.

Read the full press release here https://bit.ly/3SACCrI

Todos Medical Announces USPTO Trademark Notice of Allowance for 3CL Protease Biomarker Diagnostics TolloTest™ Todos Medical Announces USPTO Trademark Notice of Allowance for 3CL Protease Biomarker Diagnostics TolloTest™ September 27, 2022 12:02pm EDT Download as PDF New York, NY, and Tel Aviv, ISRAEL, Sept. 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensiv...

Todos Medical CEO Gerald Commissiong joins Jon Najarian to discuss the $50M Contract to Supply Tollovid™ and CBD Products to Retail Distributor Company Nerd H**p. The Company anticipates $11.5 million in revenue in the fourth quarter of 2022 from this contract as Nerd H**p commences its nationwide rollout. Watch the full interview: https://bit.ly/3dykD6t

Todos Medical: $50M Contract to Supply Tollovid™ CBD Products to Retail Distributor Nerd H**p NEW YORK, NY and TEL AVIV, ISRAEL, Sept. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnost...

Todos Medical Enters into a $50M contract to supply Tollovid™ and CBD Products to Nerd H**p, a retail distributor company looking for an immune health boost alongside their CBD product offerings. Additionally, Nerd H**p has already been contracted to install 5500 AI Retail machines in Q4/22 and Q1/23 across the United States in retail outlets including airports, shopping centers, universities, sporting venues, fitness centers, bars, and grocery outlets. The Company anticipates $11.5 million in revenue in the fourth quarter of 2022 from this contract as Nerd H**p commences its nationwide rollout.

Read the full press release: https://bit.ly/3SjjwGw

Todos Medical Enters Into $50M Contract to Supply Tollovid™ and CBD Products to Retail Distributor Company Nerd H**p Todos Medical Enters Into $50M Contract to Supply Tollovid™ and CBD Products to Retail Distributor Company Nerd H**p September 22, 2022 4:02pm EDT Download as PDF 5500 Automated Retail Machines to be Rolled out in Q4/22 and Q1/23 $11.5M in Q4/22 Revenue Expected From This Agreement NEW YORK, NY an...

Todos Medical Announces Hall of Famer Michael Irvin as Tollovid™ Sports Ambassador for Campaign. A recent market research study showed that 90%+ of both acute infection and Long COVID customers indicated they benefitted from Tollovid™. Tollovid has been Informed Sports certified as not having any performance enhancing or banned substances and is safe for athletes to use while competing.

Read the full press here https://bit.ly/3eXIyfS

Todos Medical Announces NFL Hall of Famer Michael Irvin as Tollovid™ Sports Ambassador for #TolloUp Campaign Todos Medical Announces NFL Hall of Famer Michael Irvin as Tollovid™ Sports Ambassador for Campaign September 16, 2022 7:30am EDT Download as PDF NEW YORK, NY and Tel Aviv, ISRAEL, Sept. 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive ...

Todos Medical Announces Preprint of Long COVID Case Study Participant with Confirmed Microclot and Hyperactivated Platelets who Benefitted from Tollovid™ . Alongside the COVID-19 outbreak, Long COVID proves to be a new emerging threat as millions of Americans suffer from lingering symptoms. While further research needs to be conducted regarding the underlying pathophysiology of Long COVID, many studies have revealed the presence of microclots in plasma samples from Long COVID patients.

Read the full press release here https://bit.ly/3dbKL6Y

Todos Medical Announces Preprint of Long COVID Case Study Participant with Confirmed Microclot and Hyperactivated Platelets who Benefitted from Tollovid Todos Medical Announces Preprint of Long COVID Case Study Participant with Confirmed Microclot and Hyperactivated Platelets who Benefitted from Tollovid September 15, 2022 8:41am EDT Download as PDF New York, NY, and Tel Aviv, ISRAEL, Sept. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medi...

Todos Medical Initiates Validation Plan for PCR-based Polio Testing at CLIA/CAP Laboratory Provista Diagnostics. The Company intends to validate multiple PCR assays for polio, including wastewater testing with ultra-high sensitivity. Low viral load diagnostic tests will be developed for early diagnosis and will be available for multiplexing with our other PCR panels.

Read the full press release here https://bit.ly/3S2QfQ5

Todos Medical Initiates Validation Plan for PCR-based Polio Testing at CLIA/CAP Laboratory Provista Diagnostics Todos Medical Initiates Validation Plan for PCR-based Polio Testing at CLIA/CAP Laboratory Provista Diagnostics September 14, 2022 8:55am EDT Download as PDF Follows CDC & World Health Organization's (WHO) announcement that US now meets criteria for country with circulating vaccine-derived polioviru...

Todos Medical & The Alchemist’s Kitchen to Host “Long COVID: An Integrated Approach” Event Benefitting Survivor Corps. The event will be headlined by Dr. Leo Galland, a Manhattan-based functional medicine doctor who has established a specialty in treating Long COVID patients who exhibit viral persistence among their root causes.

Read the full press here https://bit.ly/3qBpmqQ

Todos Medical’s 3CL Protease Inhibitor Supplement Tollovid™ Featured in Wellness Magazine. In the article, the authors discuss the SARS-CoV-2 virus life cycle and the importance of protease enzyme inhibition to aid in recovery.

Read the full press release here https://bit.ly/3d7qK1l

Todos Medical’s 3CL Protease Inhibitor Supplement Tollovid™ Featured in Wellness Magazine Todos Medical’s 3CL Protease Inhibitor Supplement Tollovid™ Featured in Wellness Magazine September 13, 2022 9:55am EDT Download as PDF New York, NY, and Tel Aviv, ISRAEL, Sept. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnosti...

Todos Medical Partner NLC Pharma Assigns IP for Tollovir™, Tollovid™, and TolloTest™ into JV 3CL Pharma. The assignment includes the patent applications for dual mechanism (3CL protease inhibitor and CCR5 antagonist) Phase 2 therapeutic drug candidate Tollovir™, commercial-stage 3CL protease inhibitor immune support supplement Tollovid™, and 3CL protease biomarker test TolloTest™ for SARS-CoV-2 infectivity monitoring and PASC/Long COVID viral persistence assessment (“The IP”). 3CL Pharma Ltd.

Read the full press release here https://bit.ly/3U6VeRM

Todos Medical Partner NLC Pharma Assigns IP for Tollovir™, Tollovid™, and TolloTest™ into JV 3CL Pharma Todos Medical Partner NLC Pharma Assigns IP for Tollovir™, Tollovid™, and TolloTest™ into JV 3CL Pharma September 12, 2022 9:15am EDT Download as PDF 3CL Pharma preparing crowdfunding to fund Tollovir EUA filing in hospitalized COVID patients and Tollovir, Tollovid and TolloTest clinical devel...

Todos Medical (OTCQB: TOMDF) CEO Gerald Commissiong Discusses Long COVID Economic Impact with Moneta Advisory Managing Partner Marc LoPresti. Additionally, the Company has brought forth TolloTest™, a diagnostic assay measuring 3CL protease activity which correlates with SARS-CoV-2 replication as measured by PCR ct value, that has successfully completed clinical proof of concept studies in hospitalized and outpatient settings. The Company believes TolloTest holds significant value in measuring viral activity in Long COVID.

Read the full press release here https://bit.ly/3Rz9gcS

Todos Medical CEO Discusses Long COVID Economic Impact with Moneta Advisory Managing Partner Marc LoPresti Todos Medical CEO Discusses Long COVID Economic Impact with Moneta Advisory Managing Partner Marc LoPresti September 09, 2022 12:10pm EDT Download as PDF New York, NY, and Tel Aviv, ISRAEL, Sept. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive med...

Todos Medical (OTCQB: TOMDF) announce Kingcarlx as Brand Ambassador for the Tollovid Lifestyle Campaign. Concurrent with this announcement, Todos announced that it has retained the digital investor relations marketing firm B2i Digital to assist the Company with reaching investors online as the Company looks to expand its shareholder base, primarily targeting investors who are interested in companies looking to tackle the significant Long COVID market opportunity.

Read the full press release here https://bit.ly/3ehiNXo

Todos Medical establishes botanical supplement manufacturing capabilities to support Tollovid global expansion and initiates CBD-A production. The facility is capable of producing Tollovid™, the Company’s majority owned subsidiary 3CL Pharma’s Ltd.’s 3CL protease inhibitor immune support dietary supplement, as well as other immune support supplement ingredients that could ultimately be added to new Tollovid formulations, including vitamin C and CBD-A.

Read the full press here https://bit.ly/3R3ghmb

Todos Medical Establishes Botanical Supplement Manufacturing Capabilities to Support Tollovid Global Expansion and Initiates CBD-A Production Todos Medical Establishes Botanical Supplement Manufacturing Capabilities to Support Tollovid Global Expansion and Initiates CBD-A Production August 31, 2022 9:11am EDT Download as PDF New York, NY, and Tel Aviv, ISRAEL, Aug. 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire --Todos Medical, Ltd. (OTCQB...

Todos Medical Expands COVID Onsite School Sample Collection to Include MonkeyPox Testing. Provista is able to test for both COVID-19 and MonkeyPox from the same saliva sample. The expansion of onsite sample collection support for schools to include MonkeyPox is designed for a situation where a school has a confirmed MonkeyPox case, whether from staff or students, and there is a desire from school administrators to screen staff and students entering the school in order to contain potential MonkeyPox outbreaks.

Read the full press here https://bit.ly/3craaZJ

Todos Medical Expands COVID Onsite School Sample Collection to Include MonkeyPox Testing Todos Medical Expands COVID Onsite School Sample Collection to Include MonkeyPox Testing August 29, 2022 9:15am EDT Download as PDF New York, NY, and Tel Aviv, ISRAEL, Aug. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and re...

Todos Medical Announces Saliva-Only MonkeyPox Testing at CLIA/CAP Clinical Lab Provista Diagnostics. The saliva test is intended to be used primarily in suspected cases of MonkeyPox without lesions. In cases where patients with suspected present with lesions, it is still recommended to test both lesions and saliva to determine whether the lesions contain virus and whether saliva is representative of systemic active infection.

Read the full press here https://bit.ly/3wVtdmf

Todos Medical Announces Saliva-Only MonkeyPox Testing at CLIA/CAP Clinical Lab Provista Diagnostics Todos Medical Announces Saliva-Only MonkeyPox Testing at CLIA/CAP Clinical Lab Provista Diagnostics August 26, 2022 7:18am EDT Download as PDF Lab Reaching Out to Georgia-based School Administrators to Assist with Outbreak Plans NEW YORK, NY and TEL AVIV, Israel, Aug. 26, 2022 (GLOBE NEWSWIRE) -- vi...

Todos Medical Enrolls Female Patient Unable to Secure Testing While Symptomatic for into Provista Diagnostics Case Study Series. The data could provide valuable information on the risk of to patients. The Company believes it is important for schools to plan for PCR-based COVID surveillance testing and testing and contract tracing programs in order to be able to effectively respond to the threat of viral outbreaks in their schools.

Read the full press here https://bit.ly/3ANWIbC

Todos Medical Enrolls Female Long COVID Patient Unable to Secure Testing While Symptomatic for MonkeyPox into Provista Diagnostics Case Study Series Todos Medical Enrolls Female Long COVID Patient Unable to Secure Testing While Symptomatic for MonkeyPox into Provista Diagnostics Case Study Series August 25, 2022 7:30am EDT Download as PDF Patient denied testing for weeks due to risk of physician infection & non-MSM status Amerimmune Long COVID P...

If you missed Todos Medical's Second Quarter 2022 Financial Results and Business Update Conference call yesterday, please click the link below to listen.

https://bit.ly/3pHksbb

Todos Medical Reports Second Quarter 2022 Financial Results and Business Update Conference Call August 23, 2022 - Todos Medical Reports Second Quarter 2022 Financial Results and Business Update Conference Call. ...

Todos Medical Initiates Diagnostic Case Studies After Being Approached by 4 Patients, Including 3 Women. This data is expected to uniquely position Provista in the MonkeyPox testing space by providing not only insight on potential active and recent infection, but also in the area of potential viral reservoir driving longer-term symptoms and the development of immunity from infection, and potentially Jynneos vaccination. The Company will use data gathered from these patients to support the launch of a planned blood-based IgM/IgG laboratory developed to determine active or recent infection through blood, as well as a measure of immunity status.

Read the full press here https://bit.ly/3QUfnYK

Todos Medical Initiates MonkeyPox Diagnostic Case Studies After Being Approached by 4 Patients, Including 3 Women Todos Medical Initiates MonkeyPox Diagnostic Case Studies After Being Approached by 4 Patients, Including 3 Women August 23, 2022 9:14am EDT Download as PDF New York, NY, and Tel Aviv, ISRAEL, Aug. 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive m...

Todos Medical Reports Second Quarter 2022 Financial Results and Business Update Conference Call on Tuesday, August 23 at 8:30am ET.

Read the full press here https://bit.ly/3wp4qGD

Link to join: https://bit.ly/3TcMCZl

Sequire | Audience SRAX hosts industry-specific investor events throughout the year. Sequire virtual events bring together millions of influential, forward-thinking investors and public issuers alike, creating opportunities for advancement to all who participate.

Todos Medical Announces Commercialization of Lesion and Saliva-Based Testing. Provista has also completed implementation of upgraded safety protocols to be in compliance recommended CDC protocols for which are in line with biosafety 3 level (BSL3) laboratory protocols. Provista will collect saliva samples matched with lesion swabs from confirmed cases before launching a standalone LDT targeted at identifying in the pre-symptomatic stage.

Read the full press here https://bit.ly/3Acw76D

Todos Medical Announces Commercialization of Lesion and Saliva-Based MonkeyPox PCR Testing Todos Medical Announces Commercialization of Lesion and Saliva-Based MonkeyPox PCR Testing August 22, 2022 6:30am EDT Download as PDF Provista begins validation preparations for blood-based IgM/IgG MonkeyPox LDT Company to release its Q2/2022 10Q quarterly report at 4:05 pm ET this afternoon Company...